tailieunhanh - Elsevier's Integrated Review Pharmacology with STUDENT CONSULT Online Access, 2e 2

(BQ) Part 2 book "Elsevier's integrated review pharmacology" presentation of content: Cardiovascular system, renal system, inflammatory disorders, gastrointestinal pharmacology, endocrine pharmacology, central nervous system. | Cardiovascular System CONTENTS PHARMACOLOGIC MANAGEMENT OF HYPERTENSION Diuretics b-Blockers Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Blockers Aldosterone Receptor Antagonists Renin Inhibitors a1-Receptor Blockers Calcium Channel Blockers Centrally Acting a2-Agonists Vasodilators Summary PHARMACOLOGIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION PHARMACOLOGIC MANAGEMENT OF STABLE ANGINA Nitrates: Partial Fatty Acid Oxidation Inhibitor Summary PHARMACOLOGIC MANAGEMENT OF HEART FAILURE Positive Inotropes Summary PHARMACOTHERAPY OF ANTIARRHYTHMICS Class I: Sodium Channel Blockers Class II: b-Blockers Class III: Potassium Channel Blockers Class IV: Calcium Channel Blockers Other Antiarrhythmics Summary HYPERLIPIDEMIAS Statins Fibrates Ezetimibe Bile Acid Sequestrants (Resins) Niacin Omega-3-Acid Ethyl Esters (Fish Oil) Summary COMPLEMENTARY AND ALTERNATIVE MEDICINE TOP FIVE LIST The cardiovascular system is more than just the curve, that is, the Frank-Starling curve—which states that the left ventricular end-diastolic pressure is proportional to cardiac output. In more clinical terms, pathologies that result in altered cardiac output, because of changes in stroke volume or heart rate, can be treated with drugs that affect hemodynamic parameters that control left ventricular end-diastolic pressure, such as 8 preload and afterload. However, drugs that regulate hemodynamic parameters are often ineffective and do not prolong life in patients with failing hearts. In reality, with the cardiovascular system it is all about making the failing heart more effective (., moving the Frank-Starling curve upward and to the left). This can be accomplished pharmacologically by increasing myocardial contractility through positive inotropes as well as by reducing inefficient cardiac hypertrophy via angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). Pathologies that compromise cardiac output include hypertension, .

• Y khoa - Dược
• Elseviers integrated review pharmacology
• Cardiovascular system
• renal system
• Inflammatory disorders
• Gastrointestinal pharmacology
• Endocrine pharmacology
• Central nervous system
• Pharmacodynamics and signal transduction
• Cancer and immunopharmacology
• Autonomic nervous system
• Treatment of infectious diseases
• The central nervous system
• Central nervous system trauma
• Neuropathology of vascular disease
• Human prion diseases
• Pathology of degenerative diseases
• The nervous system
• Pathology competencies
• Organ system pathology
• Human polyomavirus 2
• Domestic mammals
• Extrapyramidal feedback
• The somatic motor systems
• Autonomic components
• The central nervous system general considerations
• Imaging techniques
• BMC Cancer
• Central nervous system neoplasms
• Cancer registry
• Primary CNS tumors
• Non small cell lung cancer
• Versus afatinib
• Multiple central nervous system
• Confidence interval
• Primary central nervous system lymphoma
• Diffuse large B cell lymphoma
• Progression free survival
• Pediatric critical care medicine
• Central nervous systems
• The cardiovascular system
• Movement disorders in the ICU
• Status epilepticus
• Toxic metabolic encephalopathy
• Lippincott’s illustrated review
• Nervous system
• Basic neurophysiology
• The peripheral nervous system
• The visceral nervous system
• The spinal cord
• The meninges
• The vertebral canal
• The nerve impulse
• The cranial nerves
• Medial lemniscal system
• The special senses
• Prophylactic efficacy
• Black seed oil
• Olive oil
• Enzyme acetylcholinesterase
• BMC Pediatrics
• Central nervous system infection
• Lumbar puncture
• Viral encephalitis
• Glasgow coma score
• Unfavorable outcome
• Herpes simplex virus
• Research Electronic Data Capture
• Tumor microenvironment
• Programmed death ligand 1
• Tumor cells
• Metastatic breast cancer
• High dose intravenous methotrexat
• Breast cancer
• Sialylated N linked oligosaccharide
• High performance liquid chromatography
• Soluble PD L1
• Programmed death 1 protein
• Protecting tumor cells
• PD L1 expressing tumor cells
• Acute myeloid leukaemia
• Risk factors
• Cytogenetic abnormalities
• Molecular gene mutations
• Brain metastases
• Stem cell marker
• CNS metastases
• Decreased survival
• BMC Genomics
• Xenopus laevis
• Spinal cord injury
• Optic nerve injury
• Axon regeneration
• RNA seq
• Corticosteroid therapy
• Diagnostic rate
• Histopathological diagnosis
• Surveillance central nervous system
• Estimated percentage
• Specific treatment indication
• BMC Veterinary Research
• Mass stranding
• Striped dolphin
• Cetacean morbillivirus
• Cantabrian Sea
• Clinical course
• Isolated relapse
• High risk neuroblastoma
• Prognostic factors
• Non Hodgkin lymphoma
• Diffuse large B cell lymphomas
• B cell lymphoma
• Several clinical trials